The prognostic significance of preoperative neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma receiving hepatectomy: A systematic review and meta-analysis

被引:89
作者
Wang, Yunjiao [1 ]
Peng, Chuchu [1 ]
Cheng, Zhigang [1 ]
Wang, Ximei [1 ]
Wu, Lei [1 ]
Li, Jingyi [1 ]
Huang, Changsheng [1 ]
Guo, Qulian [1 ]
Cai, Hongwei [1 ]
机构
[1] Cent South Univ, Xiang Ya Hosp, Dept Anesthesiol, Changsha 410008, Hunan, Peoples R China
关键词
Neutrophil-lymphocyte ratio; Prognosis; Hepatocellular carcinoma; Hepatectomy; DONOR LIVER-TRANSPLANTATION; C-REACTIVE PROTEIN; TRANSARTERIAL CHEMOEMBOLIZATION; PREDICTS SURVIVAL; TUMOR RECURRENCE; INFLAMMATION; INDEX; RESECTION; MORTALITY; INDICATOR;
D O I
10.1016/j.ijsu.2018.05.022
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background and aims: Numerous reports have indicated that preoperative Neutrophil- Lymphocyte ratio (NLR) was correlated with the prognosis of hepatocellular carcinoma who underwent hepatectomy. However, the results still remained controversial. Therefore, the present meta-analysis of 17 studies was performed to evaluate the prognostic value of preoperative NLR in HCC patients. Method: Databases of PubMed, Embase, Cochrane Library and Web of Science were retrieved. Hazard Ratio (HR) or Odds Ratio (OR) with its 95% confidence intervals (CI) was used to evaluate the association between preoperative NLR and the prognosis or clinical features of HCC patients. Result: A total of 17 studies eventually were included in this meta-analysis. Elevated preoperative NLR had a close relationship with the overall survival (OS) (HR 1.52; 95% CI 1.37-1.69), recurrence-free survival (RFS) (HR 1.64; 95% CI 1.44-1.87) and disease-free survival (DFS) (HR 1.50; 95% CI 1.35-1.67) of hepatocellular carcinoma. Additionally, preoperative NLR was also associated with tumor vascular invasion (OR 2.08; 95% CI 1.60-2.70), HBV (OR 0.68; 95% CI 0.51-0.90) and large tumor size (OR: 4.07; 95% CI 2.60-6.37). Conclusion: The present meta-analysis indicated that preoperative NLR had significant association with the prognosis of hepatocellular carcinoma patients and may be an effectively prognostic indicator.
引用
收藏
页码:73 / 80
页数:8
相关论文
共 57 条
[1]   Value of neutrophil lymphocyte ratio in patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib [J].
Agilli, Mehmet ;
Aydin, Fevzi Nuri ;
Kurt, Yasemin Gulcan .
MEDICAL ONCOLOGY, 2014, 31 (07)
[2]  
[Anonymous], INFLAMMATION SCORES
[3]  
[Anonymous], 2009, SYST REV CRDS GUID U
[4]  
[Anonymous], HEPATOL RES
[5]  
[Anonymous], VERS 5 2 REV MAN REV
[6]   Preoperative neutrophil-to-lymphocyte ratio as a predictor of survival after reductive surgery plus percutaneous isolated hepatic perfusion for hepatocellular carcinoma: a retrospective analysis [J].
Arai, Keisuke ;
Fukumoto, Takumi ;
Kido, Masahiro ;
Tanaka, Motofumi ;
Kuramitsu, Kaori ;
Kinoshita, Hisoka ;
Komatsu, Shohei ;
Tsugawa, Daisuke ;
Terai, Sachio ;
Matsumoto, Taku ;
Goto, Tadahiro ;
Asari, Sadaki ;
Toyama, Hirochika ;
Ajiki, Tetsuo ;
Ku, Yonson .
SURGERY TODAY, 2017, 47 (03) :385-392
[7]   Liver transplantation for hepatocellular carcinoma: Role of inflammatory and immunological state on recurrence and prognosis [J].
Cescon, Matteo ;
Bertuzzo, Valentina Rosa ;
Ercolani, Giorgio ;
Ravaioli, Matteo ;
Odaldi, Federica ;
Pinna, Antonio Daniele .
WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (48) :9174-9182
[8]   Prognostic Nutritional Index (PNI) Predicts Tumor Recurrence of Very Early/Early Stage Hepatocellular Carcinoma After Surgical Resection [J].
Chan, Anthony W. H. ;
Chan, Stephen L. ;
Wong, Grace L. H. ;
Wong, Vincent W. S. ;
Chong, Charing C. N. ;
Lai, Paul B. S. ;
Chan, Henry L. Y. ;
To, Ka-Fai .
ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (13) :4138-4148
[9]   Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation [J].
Chen, Tsung-Ming ;
Lin, Chun-Che ;
Huang, Pi-Teh ;
Wen, Chen-Fan .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 (03) :553-561
[10]   METAANALYSIS IN CLINICAL-TRIALS [J].
DERSIMONIAN, R ;
LAIRD, N .
CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188